Who is the CEO of Jeil Pharma Holdings?

According to the DART company overview, Jeil Pharma Holdings' representative director is 한상철 (name as registered in Korean). The company was founded on 1959-03-07.

Where is Jeil Pharma Holdings listed?

Jeil Pharma Holdings trades on the Korea Exchange KOSPI market under the ticker 002620. Its fiscal year ends in December.

Does Jeil Pharma Holdings pay a dividend?

Yes. For fiscal 2025, Jeil Pharma Holdings paid a cash dividend of ₩70 per common share, a 0.9% yield as stated in its annual report, with a payout ratio of 3.1%. The prior year's dividend was ₩50.

Does Jeil Pharma Holdings have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Swung to loss (latest quarter swung to an operating loss from a profit a year earlier). These are factual flags, not investment advice.

Which companies are in the same industry as Jeil Pharma Holdings?

Under the Korean Standard Industrial Classification recorded on DART, Jeil Pharma Holdings is grouped with 10 other listed companies in professional services. The most covered in Korean news over the past 30 days are NICE Holdings, Sungchang Enterprise Holdings and Inveni.

Jeil Pharma Holdings KRX:002620KOSPI

제일파마홀딩스 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days3

DART filings, 7 days0

Articles tracked25since Sep 11

In Q2 2026, Jeil Pharma Holdings reported revenue of ₩165bn, up 3.1% year on year, and an operating loss of ₩9.9bn. Jeil Pharma Holdings (제일파마홀딩스) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 1 article. It was most often mentioned alongside Jeil Pharmaceutical.

Filing signals Swung to loss Screener

Jeil Pharma Holdings quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩165bn	+3.1%	−₩9.9bn margin −6.0%	−₩6.2bn
Q1 2026	₩150bn	-17.4%	₩3.6bn margin 2.4%	₩4.5bn
Q4 2025 derived	₩154bn	-24.3%	₩6.6bn margin 4.2%	₩12.9bn
Q3 2025	₩161bn	-15.1%	₩18.1bn margin 11.2%	₩14.2bn
Q2 2025	₩160bn	-18.9%	₩6.9bn margin 4.3%	₩2.9bn
Q1 2025	₩182bn	-3.6%	₩7.1bn margin 3.9%	₩4.6bn
Q4 2024 derived	₩204bn	+0.5%	₩3.9bn margin 1.9%	−₩32.3bn
Q3 2024	₩190bn	-2.4%	−₩3.3bn margin −1.7%	−₩5.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Jeil Pharma Holdings top stories 2 weeks, by number of outlets

1
제일파마홀딩스, 2028년 PBR 0.5배 목표…자사주 62만주 처분 검토
1 outlets · 1 articlesFirst report Oct 23 10:13 메디코파마
2
제일파마홀딩스, 2028년 PBR 0.5배 이상 목표…제품 중심 수익구조 전환
1 outlets · 1 articlesFirst report Oct 25 07:13 메디포뉴스
3
제일파마홀딩스, '저PBR' 꼬리표 떼기 안간힘
1 outlets · 1 articlesFirst report Oct 26 14:44 아시아타임즈
4
제일파마홀딩스 기업가치 제고, 제일약품 수익성 개선에 방점
1 outlets · 1 articlesFirst report Oct 27 13:13 의약뉴스Jeil Pharmaceutical

Latest Jeil Pharma Holdings news Korean headlines

Oct 2713:13

제일파마홀딩스 기업가치 제고, 제일약품 수익성 개선에 방점
의약뉴스Jeil Pharmaceutical
Oct 2614:44

제일파마홀딩스, '저PBR' 꼬리표 떼기 안간힘
아시아타임즈
Oct 2507:13

제일파마홀딩스, 2028년 PBR 0.5배 이상 목표…제품 중심 수익구조 전환
메디포뉴스
Oct 2310:13

제일파마홀딩스, 2028년 PBR 0.5배 목표…자사주 62만주 처분 검토
메디코파마
Sep 3013:32

제일파마홀딩스, 계열사와 ‘공정거래 자율준수의 날’ 개최
메디포뉴스
Sep 2919:03

제일파마홀딩스ㆍ제일약품ㆍ제일헬스사이언스, 공정거래 자율준수의 날 개최 外
의약뉴스Jeil Pharmaceutical
Sep 2917:52

[위클리오늘] 산업일반 소식_효성, 제일파마홀딩스(9.29)
위클리오늘
Sep 2917:34

제일파마홀딩스 한미사이언스 外(제약보국)
뉴스클레임Hanmi Science
Sep 2914:39

제일파마홀딩스, 전 계열사와 컴플라이언스 체계 강화....CP 우수부서 시상·공정거래 교육 진행
팍스경제TV
Sep 2914:16

제일파마홀딩스, '공정거래 자율 준수의 날' 행사
뉴시스경제
Sep 2914:16

제일파마홀딩스, ‘공정거래 자율준수의 날’ 개최…"책임 있는 기업문화 정착"
데일리한국
Sep 2912:48

제일파마홀딩스 계열사, 준법경영 체계 손질…ISO 사후심사 완료
메디컬투데이
Sep 2912:15

"글로벌 수준 준법경영 다진다"…제일파마홀딩스, 자율준수의 날 진행
더페어뉴스
Sep 2911:46
제일파마홀딩스, 전 계열사와 ‘공정거래 자율준수’ 의지 다져
의협신문
1 more on this story · 1 outlets
- 제일파마홀딩스, 전 계열사와 공정거래 자율준수 의지 다져전자신문 · Sep 29 14:49
Sep 2911:28
제일파마홀딩스, ‘공정거래 자율준수의 날’ 개최…계열사 준법경영 강화
뉴스락
5 more on this story · 5 outlets
- 제일파마홀딩스, ‘공정거래 자율준수의 날’ 개최메드월드뉴스 · Sep 29 12:08
- 제일파마홀딩스, 계열사 '공정거래 자율준수의 날' 개최아시아경제 · Sep 29 13:18
- 제일파마홀딩스, '공정거래 자율준수의 날' 개최핀포인트뉴스 · Sep 29 13:19
- 제일파마홀딩스 전 계열사 '공정거래 자율준수의 날' 개최한국경제TV · Sep 29 16:21
- 제일파마홀딩스, 컴플라이언스 강화…자율준수의 날 개최신아일보 · Sep 29 17:29
Sep 2911:24
제일파마홀딩스 계열사, 공정거래 자율준수 체계 강화
메디파나뉴스
3 more on this story · 3 outlets
- 제일파마홀딩스 계열사, 공정거래 자율준수 체계 강화…ISO 사후심사 완료PRESS9 · Sep 29 12:10
- 제일파마홀딩스, 전 계열사 공정거래 자율준수 강화뉴스1 · Sep 29 14:35
- 제일파마홀딩스, 전 계열사 ‘준법경영’ 한자리…“공정거래 자율준수 강화”인더뉴스 · Sep 29 14:59

Articles per day 2 weeks

123

125

126

127

Company profile

CEO: 한상철
Industry: Professional services
Founded: 1959-03-07
Fiscal year-end: December
Head office: 서울특별시 서초구
Website: jeilpharm.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Jeil Pharma Holdings dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩70	0.9%	3.1%
FY2024	₩50	0.6%	–
FY2023	₩50	0.4%	–

Same industry Professional services

All in industry

Company	Latest quarter op. profit	Articles 30d
NICE Holdings	₩74.9bn	6
Sungchang Enterprise Holdings	₩391m	5
Inveni	₩11.2bn	3
Soulbrain Holdings	₩31.9bn	2
Asia Holdings	₩36.4bn	1
Eusu Holdings	₩12.8bn	0
GC	₩6.6bn	0
Daesung Holdings	₩2.7bn	0

Compare Jeil Pharma Holdings side by side with these companies

Jeil Pharma Holdings DART filings

Oct 2217:19

Other 기업가치제고계획(자율공시) (PBR 개선 계획 제출 기업)
Other

Mentioned alongside 2 weeks

1 Jeil PharmaceuticalKOSPI 1

Jeil Pharma Holdings FAQ

Who is the CEO of Jeil Pharma Holdings?: According to the DART company overview, Jeil Pharma Holdings' representative director is 한상철 (name as registered in Korean). The company was founded on 1959-03-07.
Where is Jeil Pharma Holdings listed?: Jeil Pharma Holdings trades on the Korea Exchange KOSPI market under the ticker 002620. Its fiscal year ends in December.
What were Jeil Pharma Holdings' latest quarterly results?: In Q2 2026, Jeil Pharma Holdings reported revenue of ₩165bn, up 3.1% year on year, and an operating loss of ₩9.9bn. Figures come from reports filed on DART.
Does Jeil Pharma Holdings pay a dividend?: Yes. For fiscal 2025, Jeil Pharma Holdings paid a cash dividend of ₩70 per common share, a 0.9% yield as stated in its annual report, with a payout ratio of 3.1%. The prior year's dividend was ₩50.
Does Jeil Pharma Holdings have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Swung to loss (latest quarter swung to an operating loss from a profit a year earlier). These are factual flags, not investment advice.
Which companies are in the same industry as Jeil Pharma Holdings?: Under the Korean Standard Industrial Classification recorded on DART, Jeil Pharma Holdings is grouped with 10 other listed companies in professional services. The most covered in Korean news over the past 30 days are NICE Holdings, Sungchang Enterprise Holdings and Inveni.